IA
TEVA icon

Icon Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

Icon Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-99,400
Closed -$3.6M – 431
2016
Q4 		$3.6M Buy
99,400
+3,000
+3% +$120K 0.24% 131
2016
Q3 		$4.43M Buy
96,400
+55,000
+133% +$2.87M 0.29% 113
2016
Q2 		$2.08M Buy
41,400
+32,500
+365% +$1.73M 0.14% 186
2016
Q1 		$476K Buy
+8,900
New +$522K 0.03% 291

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Icon Advisers's TEVA Position: Q1 2017 in Review

Icon Advisers sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 99,400 shares — an estimated $3.6M sold.

Icon Advisers first reported a position in TEVA in Q1 2016 and held it in 4 quarters. The position peaked at $4.43M in Q3 2016. 688 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • Icon Advisers reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Icon Advisers sold 99,400 Teva Pharmaceuticals shares in Q1 2017, an estimated $3.6M.
  • Icon Advisers first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 4 quarters.
  • Icon Advisers's Teva Pharmaceuticals position peaked at $4.43M in Q3 2016.
  • 688 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Icon Advisers's 13F filing for Q1 2017, filed 4 May 2017.